Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Dooms

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Respiration; International Review of Thoracic Diseases|September 8, 2017
Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP)Hervé Dutau, David Breen, Antonio Bugalho, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Future Oncology (London, England)|March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summaryAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus ReportAnne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Respiration; International Review of Thoracic Diseases|September 8, 2017
Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP)Hervé Dutau, David Breen, Antonio Bugalho, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Future Oncology (London, England)|March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summaryAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus ReportAnne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Pageof 14